[ad_1]
“The results of HPTN 084 are incredibly important for women in Africa, where reducing the incidence of HIV remains a priority,” said Delany-Moretlwe.
“We know that adherence to a daily pill remains a challenge, and an effective injectable product like long-acting CAB is a very important additional HIV prevention option for them. We thank the women who volunteered for this study and the research staff, as this study would not have been possible without their commitment to HIV prevention. “
HPTN 084 enrolled 3,223 women at research sites in Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda, and Zimbabwe. 57% of the participants were under 25 years old, while 82% did not live with a partner.
“This announcement demonstrates the important role that research-intensive institutions and universities play in transforming society and saving human lives. Congratulations to the Wits RHI team for leading world-class research in Africa addressing the burden of disease on the continent. This incredible breakthrough will undoubtedly save the lives of many women living in sub-Saharan Africa and beyond, ”said Professor Zeblon Vilakazi. , Vice Chancellor and Principal Designee of Wits University.
The dean of the Wits faculty of health sciences, Professor Martin Veller, said: “The result of this research is once again a confirmation that South Africa has the ability to compete and collaborate with the best in the world. It is research like this that will help save and improve the lives of millions of people around the world, and especially in Africa ”.
The HPTN 084 study is jointly funded through a unique partnership of NIAID, NIMH, the Bill and Melinda Gates Foundation, and ViiV Healthcare.
[ad_2]
